Sökning: WFRF:(Palmqvist Lars 1965) > Impact of ABCB1 sin...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05860naa a2200733 4500 | |
001 | oai:DiVA.org:kth-158806 | |
003 | SwePub | |
008 | 150112s2014 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/206475 | |
009 | oai:DiVA.org:liu-112996 | |
009 | oai:prod.swepub.kib.ki.se:130134492 | |
009 | oai:DiVA.org:uu-239739 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1588062 URI |
024 | 7 | a https://doi.org/10.1111/bjh.130972 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/2064752 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1129962 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1301344922 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2397392 URI |
040 | a (SwePub)kthd (SwePub)gud (SwePub)liud (SwePub)kid (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Jakobsen Falk, Ingridu Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet4 aut0 (Swepub:liu)ingja10 |
245 | 1 0 | a Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype |
264 | c 2014-08-23 | |
264 | 1 | b Wiley,c 2014 |
338 | a print2 rdacarrier | |
500 | a QC 20150202 | |
500 | a Funding Agencies|Swedish Cancer Society; County Council of Ostergotland; AFA Insurance; Stockholm Cancer Society; Karolinska Institutet; Swedish Research Council | |
520 | a Drug resistance is a clinically relevant problem in the treatment of acute myeloid leukaemia (AML). We have previously reported a relationship between single nucleotide polymorphisms (SNPs) of ABCB1, encoding the multi-drug transporter P-glycoprotein, and overall survival (OS) in normal karyotype (NK)-AML. Here we extended this material, enabling subgroup analysis based on FLT3 and NPM1 status, to further elucidate the influence of ABCB1 SNPs. De novo NK-AML patients (n = 201) were analysed for 1199G>A, 1236C>T, 2677G>T/A and 3435C>T, and correlations to outcome were investigated. FLT3 wild-type 1236C/C patients have significantly shorter OS compared to patients carrying the variant allele; medians 20 vs. 49 months, respectively, P = 0.017. There was also an inferior outcome in FLT3 wild-type 2677G/G patients compared to patients carrying the variant allele, median OS 20 vs. 35 months, respectively, P = 0.039. This was confirmed in Cox regression analysis. Our results indicate that ABCB1 1236C>T and 2677G>T may be used as prognostic markers to distinguish relatively high risk patients in the intermediate risk FLT3 wild-type group, which may contribute to future individualizing of treatment strategies. | |
650 | 7 | a NATURVETENSKAPx Biologi0 (SwePub)1062 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Biological Sciences0 (SwePub)1062 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a acute myeloid leukaemia | |
653 | a ABCB1 | |
653 | a single nucleotide polymorphism | |
653 | a anthracyclines | |
653 | a FLT3 | |
653 | a ABCB1; FLT3; acute myeloid leukaemia; anthracyclines; single nucleotide polymorphism | |
700 | 1 | a Fyrberg, Annau Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet4 aut0 (Swepub:liu)annfy07 |
700 | 1 | a Paul, Esbjornu Karolinska Institute, Sweden4 aut |
700 | 1 | a Nahi, Harethu Karolinska Institutet4 aut |
700 | 1 | a Hermanson, Monicau Uppsala universitet,Medicinsk genetik4 aut0 (Swepub:uu)moniherm |
700 | 1 | a Rosenquist, Richard Brandellu Uppsala universitet,Hematologi och immunologi4 aut0 (Swepub:uu)richrose |
700 | 1 | a Höglund, Martinu Uppsala universitet,Hematologi4 aut0 (Swepub:uu)martinhl |
700 | 1 | a Palmqvist, Lars,d 1965u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin,Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine,University of Gothenburg, Sweden4 aut0 (Swepub:gu)xpalla |
700 | 1 | a Stockelberg, Dick,d 1950u Sahlgrens University Hospital, Sweden4 aut0 (Swepub:gu)xstodi |
700 | 1 | a Wei, Yuan,d 1978u Sahlgrens University Hospital, Sweden4 aut0 (Swepub:gu)xweiyu |
700 | 1 | a Gréen, Henriku Linköpings universitet,KTH,Genteknologi,Science for Life Laboratory, SciLifeLab,Avdelningen för läkemedelsforskning,Hälsouniversitetet,KTH Royal Institute Technology, Sweden4 aut0 (Swepub:liu)hengr89 |
700 | 1 | a Lotfi, Kouroshu Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet,Klinisk farmakologi4 aut0 (Swepub:liu)koulo97 |
710 | 2 | a Linköpings universitetb Avdelningen för läkemedelsforskning4 org |
773 | 0 | t British Journal of Haematologyd : Wileyg 167:5, s. 671-680q 167:5<671-680x 0007-1048x 1365-2141 |
856 | 4 | u http://liu.diva-portal.org/smash/get/diva2:779143/FULLTEXT01 |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:779143/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-158806 |
856 | 4 8 | u https://doi.org/10.1111/bjh.13097 |
856 | 4 8 | u https://gup.ub.gu.se/publication/206475 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-112996 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:130134492 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-239739 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy